NCT07353255 Fibrescope vs Videolaryngoscope for Nasotracheal Intubation
| NCT ID | NCT07353255 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospitals Coventry and Warwickshire NHS Trust |
| Condition | No Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2026-02-01 |
| Primary Completion | 2027-01-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2026-02-01 with a primary completion date of 2027-01-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Patients having surgery under general anaesthesia require insertion of a breathing tube to keep the airway open. The technique of inserting a breathing tube through the nose into the trachea (airway) is known as nasotracheal intubation. This is the ideal airway for surgical procedures performed inside the mouth, such as complex teeth extractions and operations on the jaw. Traditionally, the breathing tube is initially inserted blindly into the nasal cavity. Then, a video laryngoscope (a camera device) or a direct laryngoscope is used to visualise and guide the passage of tube into the trachea. This approach can be associated with difficulty passing the tube and has a high incidence of nasal trauma and nosebleed. Alternatively, a flexible fibrescope ( flexible camera device) with pre-loaded tracheal tube is passed through the nostril first under vision, gently advanced through the nasal passage and then to the trachea. Once it is correctly placed in the trachea, the breathing tube is railroaded over it. This procedure allows the clinician to visualise the nasal passage and to choose most patent nostril and hence is likely to reduce risk of nosebleed as compared blind passage of tube through the nose. A videolaryngoscope has a camera on the blade that projects the image onto a monitor screen. As this is a rigid device, it can only be inserted through the oral cavity and allows the advancement of tube into the trachea. Both these techniques are currently used in the clinical practice. However, there are no studies to inform anaesthetists whether there are any differences in the incidence of nosebleed. The investigators therefore wish to do a randomised comparison between flexible fibrescope and videolaryngocope to assess if use of the former is associated with any reduced risk or severity of nosebleed.
Eligibility Criteria
Inclusion Criteria: Patients aged 18 and above, presenting for elective surgical procedures and requiring general anaesthesia and nasal intubation will be invited to take part in the study. Exclusion Criteria: * Patients who do not want to take part or do not give consent * Patients unable to give written consent. * Patient physical status of ASA 4 and 5, * Patients deemed to require awake intubation.
Contact & Investigator
Cyprian Mendonca
STUDY DIRECTOR
University Hopsitals Coventry & Warwickshire NHS Trust
Frequently Asked Questions
Who can join the NCT07353255 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying No Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07353255 currently recruiting?
Yes, NCT07353255 is actively recruiting participants. Contact the research team at Charles.Pairaudeau2@uhcw.nhs.uk for enrollment information.
Where is the NCT07353255 trial being conducted?
This trial is being conducted at Coventry, United Kingdom.
Who is sponsoring the NCT07353255 clinical trial?
NCT07353255 is sponsored by University Hospitals Coventry and Warwickshire NHS Trust. The principal investigator is Cyprian Mendonca at University Hopsitals Coventry & Warwickshire NHS Trust. The trial plans to enroll 200 participants.